{"entity":{"id":"nct07805252","kind":"trial","name":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer","aka":[],"tldr":"A phase 1/2 trial of ODM-216 in advanced solid tumours, run by Orion Corporation, Orion Pharma, now recruiting.","summary":"Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer is a phase 1/2 interventional study registered as NCT07805252 by Orion Corporation, Orion Pharma, with 195 participants planned, started 2026-09-03 and due to reach its primary completion in 2028-01-10. Interventions recorded: ODM-216.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07805252","url":"https://clinicaltrials.gov/study/NCT07805252"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07805252","phase":"1/2","setting":"A Phase 1/2, Open-Label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumour Activity of ODM-216 in Participants With Advanced Solid Tumours","sponsor":"Orion Corporation, Orion Pharma","enrolled":195,"outcomes":[]},"route":"/trials/nct07805252/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}